1. Home
  2. PSHG vs NEUP Comparison

PSHG vs NEUP Comparison

Compare PSHG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Performance Shipping Inc.

PSHG

Performance Shipping Inc.

HOLD

Current Price

$1.67

Market Cap

20.9M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.46

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSHG
NEUP
Founded
2010
1996
Country
Greece
United States
Employees
N/A
8
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
23.1M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PSHG
NEUP
Price
$1.67
$3.46
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
47.4K
94.7K
Earning Date
05-26-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$49.57
N/A
Revenue Next Year
$2.73
N/A
P/E Ratio
$1.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$3.19
52 Week High
$2.58
$21.31

Technical Indicators

Market Signals
Indicator
PSHG
NEUP
Relative Strength Index (RSI) 51.00 35.35
Support Level $1.71 $3.19
Resistance Level $1.99 $4.58
Average True Range (ATR) 0.06 0.30
MACD 0.00 -0.03
Stochastic Oscillator 91.30 27.52

Price Performance

Historical Comparison
PSHG
NEUP

About PSHG Performance Shipping Inc.

Performance Shipping Inc is a shipping company. The company is a provider of shipping transportation services through the ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying container vessels and cargo along various shipping routes. It owns and operates Aframax and Suezmax tanker vessels.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: